Anti-TNF Treatments in Rheumatology: What They Are and How They Help
Anti-TNF therapies were among the first biologic drugs to transform the treatment of inflammatory arthritis and autoimmune disease. For many patients, they reduce pain, stiffness and fatigue, improve function, and help prevent long-term joint damage.
They have now been used for over two decades, and their role in rheumatology is well established. Understanding where anti-TNF drugs fit in treatment pathways, how well they work, and what options exist if they are not effective can help patients feel informed and reassured.
What Does “TNF” Mean?
TNF (tumour necrosis factor alpha) is a naturally occurring protein involved in the immune response. In inflammatory and autoimmune conditions, TNF is often produced in excess and plays a central role in driving:
Joint inflammation and swelling
Pain and stiffness
Damage to joints, tendons and surrounding structures
Anti-TNF drugs work by blocking this inflammatory signal, helping to bring the immune system back into balance.
What Are Anti-TNF Drugs?
Anti-TNF therapies are biologic medicines designed to target TNF specifically. They are protein-based treatments given by injection or infusion rather than tablets.
Commonly used anti-TNF drugs include:
Generic and Brand Names
Adalimumab (Humira®, Amgevita®, Hulio®, Hyrimoz®)
Etanercept (Enbrel®, Benepali®, Erelzi®)
Infliximab (Remicade®, Inflectra®, Remsima®)
Golimumab (Simponi®)
Certolizumab pegol (Cimzia®)
Many patients will encounter different brand names over time, particularly with the introduction of biosimilars.
Which Conditions Are Treated With Anti-TNF Drugs?
Anti-TNF therapies are used across a range of inflammatory and immune-mediated conditions, including:
Rheumatoid arthritis
Psoriatic arthritis and psoriasis
Ankylosing spondylitis / axial spondyloarthritis
Inflammatory bowel disease–associated arthritis
Selected other inflammatory rheumatic conditions
For most inflammatory joint diseases, anti-TNF therapy is the first-line biologic or advanced treatment once conventional treatments have been tried or are insufficient.
How Are Anti-TNF Drugs Given?
Anti-TNF therapies are given either:
As subcutaneous injections (under the skin), usually every 1–4 weeks
Or as intravenous infusions, given at longer intervals
Many patients self-administer injections at home after appropriate training. Others prefer hospital-based infusions. The method is chosen collaboratively.
How Effective Are Anti-TNF Treatments?
For many patients, anti-TNF therapy leads to:
Reduction in joint pain and swelling
Improved morning stiffness
Improved function and mobility
Reduced fatigue related to inflammation
Slowing or prevention of joint damage
Some people notice improvement within weeks, while for others the benefit develops more gradually over a few months.
Remission: An Important & Achievable Treatment Goal
In modern rheumatology, treatment is often guided by a treat-to-target approach, with remission or low disease activity as the goal.
Remission does not necessarily mean a cure, but rather:
Minimal or no signs of active inflammation
Stable symptoms
Preservation of joint function and quality of life
Many patients on anti-TNF therapy achieve sustained remission, particularly when treatment is started promptly and monitored carefully.
What If Anti-TNF Treatment Does Not Work?
Not all patients respond to their first anti-TNF drug. This is well recognised and does not mean treatment has “failed” overall.
If an anti-TNF is ineffective or not tolerated, there are several options:
Switching to a different anti-TNF drug
Some patients respond well to a second agent within the same class.Moving to a different biologic class
Other biologics target different immune pathways, such as interleukins or B-cells.Targeted synthetic treatments
Oral medications such as JAK inhibitors may be appropriate in selected cases.
This means that loss of response does not limit future options, and treatment can be adapted to the individual.
Biosimilars: What Does This Mean?
Biosimilars are highly similar versions of original biologic drugs introduced once patents expire.
Key points:
They meet strict regulatory standards
They have the same effectiveness and safety profile as originator drugs
They are widely used in routine clinical practice
Switching between an originator and a biosimilar does not usually affect disease control
Side Effects and Tolerability
Anti-TNF therapies are generally well tolerated, especially when patients are appropriately selected and monitored.
Common Side Effects
Mild injection-site reactions
Transient headaches or fatigue
Minor infections such as colds
Infection Risk
There is a small increased risk of infection, which is why:
Screening for tuberculosis and hepatitis is done before starting
Vaccination status is reviewed
Patients are monitored during treatment
Serious side effects are uncommon, and for many patients the benefits of controlling inflammation clearly outweigh the risks.
Why Careful Assessment and Monitoring Matter
Anti-TNF drugs are powerful treatments, but they are only appropriate when inflammatory disease is clearly present. Careful assessment helps ensure that:
The diagnosis is correct
Symptoms are driven by inflammation
Treatment is proportionate and appropriate
Response is monitored over time
This approach maximises benefit and reduces unnecessary exposure.
Anti-TNF Treatment and Long-Term Care
Anti-TNF therapies are available in both the private sector and the NHS. In practice, some patients may start treatment privately to facilitate assessment or initiation of therapy.
However, for most patients with long-term inflammatory disease, ongoing care is usually transferred to the NHS, where biologic treatment can be continued with appropriate monitoring and support. Clear communication and continuity of care are important during this process.
Trusted Patient Information Resources
Many patients find it helpful to read further information from reliable, evidence-based sources alongside specialist advice. The following organisations provide high-quality patient resources on anti-TNF treatments and inflammatory arthritis:
Versus Arthritis – Biologic and Targeted Treatments
https://versusarthritis.org/about-arthritis/treatments/drugs/biologic-therapies/
Clear explanations of biologic drugs, including anti-TNF therapies, how they work, and what to expect from treatment.NHS – Biologic Medicines
https://www.nhs.uk/conditions/biologic-therapies/
An overview of biologic treatments used across inflammatory and autoimmune conditions, including safety and monitoring.British Society for Rheumatology – Patient Information
https://www.rheumatology.org.uk/patients
Evidence-based patient information developed by UK rheumatology specialists.National Rheumatoid Arthritis Society (NRAS)
https://nras.org.uk
Practical support and education for people living with inflammatory arthritis, including biologic treatments.
These resources are intended to support understanding and discussion. Treatment decisions are always individual and should be made in the context of a specialist assessment.
In Summary
Anti-TNF drugs are a cornerstone of modern rheumatology
They are usually the first-line biologic treatment for inflammatory arthritis
Many patients achieve good disease control or remission
If one anti-TNF does not work, other effective options are available
Most patients tolerate treatment well
Long-term care is typically delivered within the NHS
When used appropriately, anti-TNF therapies can dramatically improve symptoms, function and long-term outcomes for people with inflammatory joint disease.
Please note, these posts are for general information only and do not constitute medical advice. Dr Singh would encourage you to speak to your healthcare professional to be assessed and managed for your specific symptoms.